PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.62%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
8.49%
Other expenses growth 0-10% reflects moderate increase. Benjamin Graham would investigate nature of expenses.
-3.29%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-3.29%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-91.94%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
No Data
No Data available this quarter, please select a different quarter.
3.29%
EBITDA growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
No Data
No Data available this quarter, please select a different quarter.
3.29%
Operating income growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
No Data
No Data available this quarter, please select a different quarter.
-3.29%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.01%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
27.01%
Net income growth above 15% demonstrates exceptional bottom-line expansion. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
26.90%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
26.90%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.